Market News How it works Learn FAQ
| GPUS 0.1689 34.05% | XXII 0.1977 -8.34% | SHFS 0.1324 -61.39% | NVD 4.19 0.96% | LUCD 0.411 25.42% | SPCX 147.49 1.89% | T 20.93 -7.96% | SOXL 83.56 1.77% | NU 15.16 2.92% | NOK 8.14 3.30% | EWZ 42.59 1.77% | NVDA 210.96 -0.59% | RIME 0.106 -12.90% | INTC 86.96 1.72% | TSLG 4.87 -1.62% | AAL 12.11 -3.89% | BBD 4.07 3.04% | STLA 4.06 -4.81% | SOXS 52.46 -1.85% | RWM 14.55 0.34% | HYG 77.05 -0.06% | MYND 0.24 47.42% | BITO 10.83 -0.28% | SPDN 8.54 0.47% | YFOR 0.2236 -1.58% | RBNE 0.19 -2.56% | TQQQ 66.29 -0.20% | VZ 44.66 -1.19% | TSLL 9.76 -1.21% | SPTI 27.63 -0.11% | YMAT 2.05 6.77% | CRWV 54.235 -2.46% | INFY 12.35 -6.58% | RIG 6.41 5.43% | F 11.6 -2.85% | SQQQ 39.68 0.20% | AIOK 12.02 182.82% | ONDS 6.2 2.99% | AAPL 347.725 -0.14% | LABT 0.31 -36.67% | CDE 13.45 -3.10% | PCG 12.63 -2.70% | GRAB 2.79 -2.11% | SOFI 14.615 -1.05% | XLE 69.33 2.60% | IREN 24.905 -2.37% | QID 14.55 0.14% | RKT 11.73 -0.09% | WULF 11.32 0.00% | BE 193.3 -11.24%
CACalciMedica, Inc. logo

CalciMedica, Inc. (CALC)

NASDAQ Capital Market · Currency in USD
$1.23 ▲ +0.08 (+6.96%)
At close: Oct 23, 4:00 PM ET. Market closed.
$1.30 ▲ +0.07 (+5.69%)
After hours: Oct 23, 5:48 PM ET

Summary

Previous Close
$1.15
Open
$1.19
Day's Range
$1.16 – $1.33
52 Week Range
$1.00 – $36.00
Volume
107,543
Avg. Volume
212,049
Market Cap
$3.87M
Beta (5Y Monthly)
1.12
PE Ratio (TTM)
--
EPS (TTM)
-$6.21
Earnings Date
Nov 11, 2026
Forward Dividend & Yield
--
Ex-Dividend Date
--
1y Target Est
$266.00

Profile: CalciMedica, Inc.

Sector
Healthcare
Industry
Biotechnology
Full-time employees
15
CEO
A. Rachel Leheny

CalciMedica, Inc., a clinical-stage biotechnology company headquartered in La Jolla, California, is focused on creating treatments for life-threatening inflammatory diseases that currently lack adequate therapies. The company's proprietary approach involves blocking calcium release-activated (CRAC) channels, a mechanism designed to modulate the immune system and protect against cellular and tissue damage in these severe conditions. Their primary experimental drug, Auxora, is an intravenously administered, proprietary CRAC channel inhibitor being developed for the treatment of acute pancreatitis, including its asparaginase-associated form, and acute kidney injury.

Earnings

Next report: Wed, Nov 11, 2026
EPS estimate -$1.28
DateEst.Actual
Aug 11, 2026-$1.43-$2.25Miss
May 13, 2026-$1.40-$1.50Miss
Mar 26, 2026-$2.75-$3.40Miss
Nov 12, 2025-$2.06-$2.60Miss
Aug 11, 2025-$2.00-$2.00Beat
May 14, 2025-$2.15-$1.80Beat

Analyst view

Consensus price target
$266.00 ▲ +21,526.0%
Range $14.00 – $392.00
Rating: Buy
Buy 67% · Hold 33% · Sell 0%

Get free alerts on CALC and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.